A Phase 1 interventional study of Clarithromycin and Amoxicillin in Helicobacter Pylori, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-08-31.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Helicobacter Pylori (H Pylori) is a bug found in the digestive system. It can cause soreness and redness in the stomach (gastritis). It can also cause ulcers in the stomach and other parts of the digestive system. Vonoprazan is a medicine to treat people with H Pylori. It is taken together with other medicines to fight infections caused by H Pylori.
The main aim of this study is to learn if vonoprazan changes how the other medicines are processed by the body. It will be compared with another medicine called esomeprazole. Other aims are to check for side effects from the study medicines.
At the first visit, the study doctor will check who can take part. Participants who take part will be picked for 1 of 2 treatments by chance.
Both treatments will last for 14 days. Participants will stay in the clinic throughout their treatment.
After treatment, the clinic staff will telephone the participants 2 days later for a check-up. The participants will visit the clinic 4 weeks later for a final check-up.
This is a study in healthy participants with Helicobacter pylori (HP positive) to evaluate the safety, tolerability and PK of a quadruple therapy with bismuth, clarithromycin, amoxicillin, and vonoprazan versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and esomeprazole.
The treatment phase consists of quadruple therapy twice daily (BID) with bismuth potassium citrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and vonoprazan (20 mg) (Group B) or quadruple therapy BID with bismuth potassium citrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and esomeprazole (20 mg) (Group A) from Days 1 to 14. Participants will be discharged on Day 15 after all procedures have been performed.
This single-center will be conducted in China. Participants will remain confined to the study site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and return on Day 42 for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clarithromycin 500 milligram (mg), tablets, orally, BID, along with amoxicillin 1000 mg, capsules, orally, BID, bismuth potassium citrate 600 mg, capsules, orally, BID, and vonoprazan 20 mg, tablets, orally, BID on Days 1 to 14.
Drug: Clarithromycin · Drug: Amoxicillin · Drug: Bismuth potassium citrate · Drug: Vonoprazan
Clarithromycin 500 mg, tablets, orally, BID, along with amoxicillin 1000 mg, capsules, orally, BID, bismuth potassium citrate 600 mg, capsules, orally, BID, and esomeprazole 20 mg, tablets, orally, BID on Days 1 to 14.
Drug: Clarithromycin · Drug: Amoxicillin · Drug: Bismuth potassium citrate · Drug: Esomeprazole
Clarithromycin tablets.
Amoxicillin capsules.
Bismuth potassium citrate tablets.
Esomeprazole tablets.
Vonoprazan tablets.
Also known as: TAK-438
Cmax: Maximum Observed Plasma Concentration for Bismuth
Time frame: Day 14: 0 to 12 hours after the morning dose
AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval τ for Bismuth
Time frame: Day 14: 0 to 12 hours after the morning dose
Aeτ: Total Amount of Bismuth Excreted in Urine During a Dosing Interval τ for Bismuth
Time frame: Day 14: 0 to 12 hours after the morning dose
Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug.
Time frame: From the first dose of study drug up to Day 17
Percentage of Participants Who Discontinued Study Drug Due to a Treatment-Emergent Adverse Event (TEAE)
Time frame: From the first dose of study drug up to Day 17
Participants took part in the study at 1 investigative site in China from 06 April 2021 to 05 November 2021.
| Milestone | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole |
|---|---|---|
| Started | 22 | 22 |
| Completed | 20 | 17 |
| Not completed | 2 | 5 |
| Withdrew: Pretreatment event/adverse event | 0 | 1 |
| Withdrew: Liver function test abnormalities | 2 | 4 |
| nanogram per milliliter (ng/mL) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Bismuth | 42.8 (32.6 to 56.2) | 32.9 (24.7 to 43.8) |
| hour*nanogram/milliliter (h*ng/mL) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole |
|---|---|---|
| AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval τ for Bismuth | 146 (117 to 183) | 137 (108 to 173) |
| micrograms (μg) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole |
|---|---|---|
| Aeτ: Total Amount of Bismuth Excreted in Urine During a Dosing Interval τ for Bismuth | 1026 ± 546.0 | 1037 ± 562.5 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug.
| percentage of participants | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole |
|---|---|---|
| Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) | 95.5 | 95.5 |
| percentage of participants | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole |
|---|---|---|
| Percentage of Participants Who Discontinued Study Drug Due to a Treatment-Emergent Adverse Event (TEAE) | 9.1 | 22.7 |
Collected over From the first dose of study drug up to Day 17. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | 0/22 (0%) | 0/22 (0%) | 21/22 (95.5%) |
| Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | 0/22 (0%) | 0/22 (0%) | 21/22 (95.5%) |
| Event | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole |
|---|---|---|
| DysgeusiaNervous system disorders | 15/22 | 18/22 |
| Alanine aminotransferase increasedInvestigations | 9/22 | 8/22 |
| Aspartate aminotransferase increasedInvestigations | 9/22 | 7/22 |
| NauseaGastrointestinal disorders | 1/22 | 5/22 |
| HyponatraemiaMetabolism and nutrition disorders | 3/22 | 4/22 |
| Alpha hydroxybutyrate dehydrogenase increasedInvestigations | 1/22 | 3/22 |
| Amylase increasedInvestigations | 1/22 | 3/22 |
| Faeces discolouredGastrointestinal disorders | 3/22 | 1/22 |
| HungerGeneral disorders | 1/22 | 3/22 |
| PruritusSkin and subcutaneous tissue disorders | 0/22 | 3/22 |
Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | Total |
|---|---|---|---|
| Mean | 34.5 ± 9.60 | 31.6 ± 9.59 | 33.1 ± 9.60 |
| Sex: Female, Male(Participants) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | Total |
|---|---|---|---|
| Female | 8 | 9 | 17 |
| Male | 14 | 13 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 22 | 22 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 22 | 22 | 44 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | Total |
|---|---|---|---|
| China | 22 | 22 | 44 |
| Height(cm) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | Total |
|---|---|---|---|
| Mean | 167.2 ± 6.58 | 165.6 ± 7.17 | 166.4 ± 6.85 |
| Weight(kg) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | Total |
|---|---|---|---|
| Mean | 62.8 ± 9.23 | 63.2 ± 8.23 | 63.0 ± 8.64 |
| Body Mass Index (BMI)(kg/m^2) | Clarithromycin + Amoxicillin + Bismuth + Vonoprazan | Clarithromycin + Amoxicillin + Bismuth + Esomeprazole | Total |
|---|---|---|---|
| Mean | 22.4 ± 2.07 | 23.1 ± 3.09 | 22.7 ± 2.63 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2021 to primary completion in Sep 2021, 5 months.
Results were first posted in Aug 2023, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan